How access works
The Substance Access Beneficiary Engagement Incentive is an optional feature of three CMS Innovation Center models. An approved model participant that elects the incentive may discuss certain hemp products with eligible patients and, subject to CMS requirements and safeguards, furnish an eligible product directly. This is not Medicare coverage or reimbursement for the product.
Important evidence context. Micelle 60 and FDA-approved prescription cannabidiol are separate products. No clinical, pharmacokinetic, exposure, efficacy, safety or comparability bridge has been established between them. Micelle 60 is not FDA approved, and no clinical benefit or product-specific safety profile has been established for it.
How we review this information
Who can offer it
The incentive is available to approved participants in the ACO REACH Model and Enhancing Oncology Model from April 1, 2026, and in the Long-term Enhance ACO Design Model from January 1, 2027. A participant may offer it only after electing the incentive for the applicable performance period, maintaining a CMS-required Implementation Plan and receiving CMS approval. [3]Source: Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive. Last checked: .
Who can receive it
Only patients aligned with an approved participating organization that has elected the incentive may receive it. Additional requirements appear in the applicable model documents and the organization’s CMS-approved Implementation Plan.
CMS says the general criteria include being 18 or older, not meeting the model’s frailty exclusion, not having a specified disqualifying condition, and not being pregnant or breastfeeding. The participating organization applies these criteria. Micelle Therapeutics does not determine whether a patient is eligible. [3]Source: Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive. Last checked: .
What the physician must do
A physician must determine that use is appropriate and document shared decision-making. At a minimum, the discussion covers potential benefits and risks, the patient’s goals and preferences, current medicines and possible interactions, and a plan for follow-up. Any eligible product must be furnished directly by a qualified physician affiliated with the participating organization. [3]Source: Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive. Last checked: .
What it costs
The participating organization is responsible for procurement and operations. Medicare pays the organization $0 for the product. CMS permits a participant to furnish up to $500 in product value per eligible patient per year. The $500 figure is an annual ceiling-not a guaranteed allowance, cash payment, reimbursement or product price. Patients should not be directed to buy a product at retail and submit a receipt under this incentive. [3]Source: Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive. Last checked: .
What an eligible product is
Under CMS’s current definition, an eligible product must be a federally legal hemp-derived product containing no more than 0.3% delta-9 THC on a dry-weight basis and must comply with applicable state and local laws. It cannot be inhaled. An orally administered product cannot exceed CMS’s current 3 mg-per-serving limit for the specified tetrahydrocannabinols, and it cannot contain cannabinoids that are not naturally produced, or capable of being produced, by the cannabis plant during cultivation. [3]Source: Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive. Last checked: .
CMS also requires products to come from a legally compliant source and to undergo third-party testing for potency, contaminants and microbial hazards, with negative results for contaminants and microbial hazards. These requirements do not establish that Micelle 60 is eligible or available through any participant. [3]Source: Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive. Last checked: .
Federal law is changing
Federal hemp law changes in two stages. Beginning November 12, 2026, the Section 781 amendments apply only to the two cross-referenced exclusions for certain intermediate and final hemp-derived cannabinoid products containing cannabinoids that Cannabis sativa L. cannot naturally produce. Public Law 119-103 Section 2019 sets December 11, 2026 as the transition date for the broader amendments, including the finished-product restriction for more than 0.4 mg combined total per container of total tetrahydrocannabinols, including THCA, plus the other cannabinoids specified in the statute. This federal threshold does not by itself establish product compliance or CMS eligibility. CMS says it will adjust its definition when applicable legal limits change. [3-5]Source: Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive.; Public Law 119-37, §781. Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. November 12, 2025; 139 Stat. 558-561.; H.R. 6500 (ENR), Continuing Appropriations and Extensions Act, 2027, §2019, “Section 781 Extension”; enacted as Public Law 119-103, 140 Stat. 987, September 2, 2026. Official enrolled text; enactment independently confirmed. Last checked: .
What the incentive is not
This incentive is not Medicare coverage or reimbursement for a hemp product. CMS approval of an organization’s Implementation Plan does not make a product an FDA-approved treatment. FDA’s April 1, 2026 conditional enforcement policy for certain oral hemp-derived CBD products does not approve a product or establish general legality. [1, 3, 6]Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).; Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive.; U.S. Food and Drug Administration. Hemp-Derived Cannabidiol Products in Medical Research Models. April 1, 2026. Last checked: .
If you believe your care organization participates, ask your care team. Micelle Therapeutics cannot determine whether you are eligible.
Sources: [1, 3-6]. Evidence last checked September 16, 2026.Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).; Centers for Medicare & Medicaid Services. Substance Access Beneficiary Engagement Incentive.; Public Law 119-37, §781. Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. November 12, 2025; 139 Stat. 558-561.; H.R. 6500 (ENR), Continuing Appropriations and Extensions Act, 2027, §2019, “Section 781 Extension”; enacted as Public Law 119-103, 140 Stat. 987, September 2, 2026. Official enrolled text; enactment independently confirmed.; U.S. Food and Drug Administration. Hemp-Derived Cannabidiol Products in Medical Research Models. April 1, 2026. Last checked: .